We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Review of Multimodality Management of Anaplastic Thyroid Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00280852
First Posted: January 24, 2006
Last Update Posted: November 21, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AHS Cancer Control Alberta
  Purpose
To describe the outcome of patients with anaplastic thyroid cancer treated with hyperfractionated radiotherapy and concomitant chemotherapy

Condition
Anaplastic Thyroid Cancer

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 5
Study Start Date: January 2006
Study Completion Date: June 2006
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
anaplastic thyroid cancer
Criteria

Inclusion Criteria:

  • anaplastic thyroid cancer treated with multimodality treatment

Exclusion Criteria:

  • differentiated thyroid cancer
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00280852


Locations
Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Sponsors and Collaborators
Alberta Health Services
Investigators
Principal Investigator: Harold Lau, MD Alberta Cancerboard
  More Information

ClinicalTrials.gov Identifier: NCT00280852     History of Changes
Other Study ID Numbers: 18940
First Submitted: January 20, 2006
First Posted: January 24, 2006
Last Update Posted: November 21, 2011
Last Verified: July 2011

Keywords provided by AHS Cancer Control Alberta:
anaplastic thyroid cancer
chemotherapy
radiotherapy

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Thyroid Carcinoma, Anaplastic
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type